Mehdi Hamadani: Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide
Mehdi Hamadani shared on X:
“Our new BMT CTN 1703 analysis busts a few myths: QOL improved with ptCY, Cystitis not worse 2yr GRFS superior 42% vs 29%, p=0.001 ptCY relapse NOT higher, Shernan Holtan, Javier Bolaños Meade, TY to Mike Martens for elegant analysis.”
Authors: Shernan G. Holtan, Javier Bolaños-Meade, Monzr M. Al Malki, Juan Wu, Carrie L. Kitko, Ran Reshef, Andrew R. Rezvani, Brian C. Shaffer, Melhem M. Solh, Janny M. Yao, Lyndsey Runaas, Hany Elmariah, Karilyn T. Larkin, Najla El Jurdi, Mahasweta Gooptu, Alison W. Loren, Aric C. Hall, Amin M. Alousi, Omer Jamy, William Clark, Leslie Kean, Ami S. Bhatt, Miguel-Angel Perales, Kristy Applegate, Yvonne Adeduni Efebera, Eric Leifer, Richard J. Jones, Mary M. Horowitz, Deborah Mattila, Wael Saber, Mehdi Hamadani, and Michael J. Martens.
Mehdi Hamadani is a Professor of Internal Medicine at the Medical College of Wisconsin, where he also serves as Director of the Blood and Marrow Transplant (BMT) and Cellular Therapy Program. Additionally, he is the Associate Scientific Director at the Center for International Blood and Marrow Transplantation Research. He holds leadership roles within the American Society for Transplantation and Cellular Therapy (ASTCT), including Secretary and Co-Chair of its scientific journal.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023